netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Notes:

Patient Counselling Resource

RightBreathe: www.rightbreathe.com

  • RightBreathe is a new website and application about inhaler devices launched on 20th February 2017. It has significant MI input and collaboration between multidisciplinary healthcare professionals.
  • RightBreathe covers each and every inhaler and spacer device licensed in the UK for treating asthma and COPD. It presents specific, tailored information on each option in a standardised format and with assured quality.
  • RightBreathe enables clinicians and patients to search and filter the options to suit individual circumstances and patients’ needs.
Chapter Links...
 Details...
03.01.04  Expand sub section  Compound bronchodilator preparations
Tiotropium & olodaterol
(Combined Long Acting Beta2 Agonist and Long Acting Muscarinic Antagonist - LABA + LAMA)
View adult BNF View SPC online View childrens BNF
Formulary
Green

Please follow COPD Inhaler Device Pathway in the appendix to help maintain device consistency and follow associated pathway in a step wise approach.

Spiolto Respimat®

2.5mcg tiotropium/2.5mcg olodaterol (Aerosol inhaler)

 
   
Aclidinium and formoterol inhaler
(Combined Long Acting Beta2 Agonist and Long Acting Muscarinic Antagonist - LABA + LAMA)
View adult BNF View SPC online View childrens BNF
Formulary
Green

Please follow COPD Inhaler Device Pathway in the appendix to help maintain device consistency and follow associated pathway in a step wise approach.

Duaklir Genuair®

340mcg aclidinium/12mcg formoterol (DPI - Dry powder inhaler)

 
   
Glycopyrronium/ indacaterol inhaler
View adult BNF View SPC online View childrens BNF
Formulary
Green

Please follow COPD Inhaler Device Pathway in the appendix to help maintain device consistency and follow associated pathway in a step wise approach.

Ultibro Breezhaler®

110mcg indacaterol/50mcg glcopyrronium

Hard capsule (inhalation powder) (DPI - Dry powder inhaler)

 
   
Umeclidinium & vilanterol (Anoro Ellipta)
View adult BNF View SPC online View childrens BNF
Formulary
Green

Please follow COPD Inhaler Device Pathway in the appendix to help maintain device consistency and follow associated pathway in a step wise approach.

Anoro Ellipta®

22mcg umeclidinium/55mcg vilanterol (DPI - Dry powder inhaler)

 
   
 ....
 Non Formulary Items
Duovent

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ipratropium bromide with salbutamol  (Combivent, Salipraneb)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary